Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus
Clinical trial NCT06731218 · RECRUITING
Trial details
- NCT number
- NCT06731218
- Sponsor
- Hangzhou Reprogenix Bioscience, Inc
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-17
- Primary completion
- 2027-12-31
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.